Jan is Executive Chairman and member of the Board of Directors of GentiBio. Previously, he was the CEO and President of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, and took the company from a $16M market capitalization to a $2.3B acquisition by Pfizer in two years. Before Trillium, Jan was the CEO of Tal Medical, a private clinical-stage neuromodulation company, and a leading partner in the healthcare practice of Bain & Company. In addition to GentiBio, Jan is an Executive Chairman at DEM Biopharma. He holds an MBA from Harvard Business School, and PhD in Economics from the Economic University, Slovakia.
Jan Skvarka, PhD, MBA
Executive Chairman of the Board